Centene Corporation Company Profile (NYSE:CNC)

Centene Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

Centene Corporation (NYSE:CNC) issued its earnings results on Tuesday, July, 25th. The company reported $1.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.30 by $0.29. The firm earned $11.95 billion during the quarter, compared to analysts' expectations of $11.69 billion. Centene Corporation had a net margin of 1.72% and a return on equity of 14.62%. The firm's revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.29 earnings per share. View Centene Corporation's Earnings History.

Centene Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Centene Corporation.

Centene Corporation issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $4.70-5.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.79. The company issued revenue guidance of $46.4-47.2 billion, compared to the consensus revenue estimate of $46.82 billion.

18 brokerages have issued twelve-month price targets for Centene Corporation's shares. Their forecasts range from $64.00 to $105.00. On average, they anticipate Centene Corporation's share price to reach $85.60 in the next year. View Analyst Ratings for Centene Corporation.

Here are some recent quotes from research analysts about Centene Corporation stock:

• 1. According to Zacks Investment Research, "Centene’ searnings per share of $1.59 surpassed the Zacks Consensus Estimate by 22.3% and improved 23.2% year over year on the back of higher revenues. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion and asset base. Its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also impresses. Year to date, the stock rallied 47%, outpacing 23% gain of the industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. However, it suffers from rising level of debt and increasing borrowing cost that keeps draining the bottom-line. Rising level of  acquisition related expenses continue to bother." (7/27/2017)
• 2. Cantor Fitzgerald analysts commented, "This morning, CNC reported 2Q17 results. Revenue of $11.95 billion was slightly ahead of FactSet consensus. Adjusted EPS was $1.59 vs. our estimate of $1.25 and consensus of $1.30." (7/25/2017)
• 3. Leerink Swann analysts commented, "We reiterate our Market Perform rating on CNC while raising PT to $64 from $62 after the 4Q report and almost 6% move up yesterday." (2/9/2017)

Some companies that are related to Centene Corporation include Incyte Corporation (INCY), Grifols, S.A. (GRFS), Illumina (ILMN), Zimmer Biomet Holdings (ZBH), Edwards Lifesciences Corporation (EW), Cardinal Health (CAH), Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Laboratory Corporation of America Holdings (LH), Smith & Nephew SNATS (SNN), Eisai Co., Ltd (ESALY), BioMarin Pharmaceutical (BMRN), Quest Diagnostics Incorporated (DGX), Henry Schein (HSIC), IDEXX Laboratories (IDXX) and DENTSPLY SIRONA (XRAY).

Centene Corporation's management team includes the folowing people:

• Michael F. Neidorff, Chairman of the Board, President, Chief Executive Officer
• Jeffrey A. Schwaneke CPA, Chief Financial Officer, Executive Vice President, Treasurer
• Keith H. Williamson, Executive Vice President, General Counsel, Secretary
• Christopher D. Bowers, Executive Vice President - Marketing
• Cynthia J. Brinkley, Executive Vice President - Global Corporate Development
• Jesse N. Hunter, Executive Vice President - Products
• Christopher R. Isaak, Senior Vice President, Corporate Controller and Chief Accounting Officer
• Mark J. Brooks, Senior Vice President, Chief Information Officer
• Christopher A. Koster, Senior Vice President - Corporate Services
• Orlando Ayala, Independent Director

Centene Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include Vaughan Nelson Investment Management L.P. (0.34%), Bank of Montreal Can (0.22%), First Quadrant L P CA (0.21%), Cortland Associates Inc. MO (0.19%), Russell Investments Group Ltd. (0.17%) and BB&T Corp (0.12%). Company insiders that own Centene Corporation stock include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Institutional Ownership Trends for Centene Corporation.

Centene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Tavio Capital LLC, Assenagon Asset Management S.A., Cortland Associates Inc. MO, APG Asset Management N.V., Osborne Partners Capital Management LLC, Vaughan Nelson Investment Management L.P., Handelsbanken Fonder AB and NGAM Advisors L.P.. Company insiders that have sold Centene Corporation stock in the last year include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Insider Buying and Selling for Centene Corporation.

Centene Corporation's stock was acquired by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Bank of Montreal Can, Strs Ohio, Harbour Capital Advisors LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Acadian Asset Management LLC, Russell Investments Group Ltd. and Meeder Asset Management Inc.. View Insider Buying and Selling for Centene Corporation.

Shares of Centene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Centene Corporation stock can currently be purchased for approximately $81.17.